UK's RECOVERY trial finds no clinical benefit from use of lopinavir-ritonavir in hospitalized COVID-19 patients

On 29 June, 2020 the third set of findings was released from the UK's COVID-19 RECOVERY trial. The findings revealed no clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied:

"A total of 1596 patients were randomised to lopinavir-ritonavir and compared with 3376 patients randomised to usual care alone. Of these patients, 4% required invasive mechanical ventilation when they entered the trial, 70% required oxygen alone, and 26% did not require any respiratory intervention. There was no significant difference in the primary endpoint of 28-day mortality (22.1% lopinavir-ritonavir vs. 21.3% usual care; relative risk 1.04 [95% confidence interval 0.91-1.18]; p=0.58) and the results were consistent in different subgroups of patients. There was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay." 

Read the full statement here.